Research ExplorerPublicationsOutcomes after allogeneic hematopoietic cell transplant in p...

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Standard

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. / Ortí, Guillermo; Gras, Luuk; Zinger, Nienke; Finazzi, Maria Chiara; Sockel, Katja; Robin, Marie; Forcade, Edouard; Avenoso, Daniele; Kröger, Nicolaus; Finke, Jürgen; Radujkovic, Aleksandar; Hunault-Berger, Mathilde; Schroyens, Wilfried; Zuckerman, Tsila; Bourhis, Jean Henri; Chalandon, Yves; Bloor, Adrian; Schots, Rik; de Wreede, Liesbeth C; Drozd-Sokolowska, Joana; Raj, Kavita; Polverelli, Nicola; Czerw, Tomasz; Hernández-Boluda, Juan Carlos; McLornan, Donal; Yakoub-Agha, Ibrahim.

In: AM J HEMATOL, Vol. 98, No. 4, 04.2023, p. 628-638.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ortí, G, Gras, L, Zinger, N, Finazzi, MC, Sockel, K, Robin, M, Forcade, E, Avenoso, D, Kröger, N, Finke, J, Radujkovic, A, Hunault-Berger, M, Schroyens, W, Zuckerman, T, Bourhis, JH, Chalandon, Y, Bloor, A, Schots, R, de Wreede, LC, Drozd-Sokolowska, J, Raj, K, Polverelli, N, Czerw, T, Hernández-Boluda, JC, McLornan, D & Yakoub-Agha, I 2023, 'Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation', AM J HEMATOL, vol. 98, no. 4, pp. 628-638. https://doi.org/10.1002/ajh.26833

APA

Ortí, G., Gras, L., Zinger, N., Finazzi, M. C., Sockel, K., Robin, M., Forcade, E., Avenoso, D., Kröger, N., Finke, J., Radujkovic, A., Hunault-Berger, M., Schroyens, W., Zuckerman, T., Bourhis, J. H., Chalandon, Y., Bloor, A., Schots, R., de Wreede, L. C., ... Yakoub-Agha, I. (2023). Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. AM J HEMATOL, 98(4), 628-638. https://doi.org/10.1002/ajh.26833

Vancouver

Ortí G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. AM J HEMATOL. 2023 Apr;98(4):628-638. https://doi.org/10.1002/ajh.26833

Bibtex

@article{1abe55545cb846f08e200b4b6726a6b4,
title = "Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation",
abstract = "Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.",
keywords = "Humans, Retrospective Studies, Hematopoietic Stem Cell Transplantation/adverse effects, Transplantation, Homologous/adverse effects, Blast Crisis/therapy, Bone Marrow, Neoplasm Recurrence, Local/etiology, Myeloproliferative Disorders/therapy, Transplantation Conditioning",
author = "Guillermo Ort{\'i} and Luuk Gras and Nienke Zinger and Finazzi, {Maria Chiara} and Katja Sockel and Marie Robin and Edouard Forcade and Daniele Avenoso and Nicolaus Kr{\"o}ger and J{\"u}rgen Finke and Aleksandar Radujkovic and Mathilde Hunault-Berger and Wilfried Schroyens and Tsila Zuckerman and Bourhis, {Jean Henri} and Yves Chalandon and Adrian Bloor and Rik Schots and {de Wreede}, {Liesbeth C} and Joana Drozd-Sokolowska and Kavita Raj and Nicola Polverelli and Tomasz Czerw and Hern{\'a}ndez-Boluda, {Juan Carlos} and Donal McLornan and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2023 Wiley Periodicals LLC.",
year = "2023",
month = apr,
doi = "10.1002/ajh.26833",
language = "English",
volume = "98",
pages = "628--638",
journal = "AM J HEMATOL",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

AU - Ortí, Guillermo

AU - Gras, Luuk

AU - Zinger, Nienke

AU - Finazzi, Maria Chiara

AU - Sockel, Katja

AU - Robin, Marie

AU - Forcade, Edouard

AU - Avenoso, Daniele

AU - Kröger, Nicolaus

AU - Finke, Jürgen

AU - Radujkovic, Aleksandar

AU - Hunault-Berger, Mathilde

AU - Schroyens, Wilfried

AU - Zuckerman, Tsila

AU - Bourhis, Jean Henri

AU - Chalandon, Yves

AU - Bloor, Adrian

AU - Schots, Rik

AU - de Wreede, Liesbeth C

AU - Drozd-Sokolowska, Joana

AU - Raj, Kavita

AU - Polverelli, Nicola

AU - Czerw, Tomasz

AU - Hernández-Boluda, Juan Carlos

AU - McLornan, Donal

AU - Yakoub-Agha, Ibrahim

N1 - © 2023 Wiley Periodicals LLC.

PY - 2023/4

Y1 - 2023/4

N2 - Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.

AB - Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.

KW - Humans

KW - Retrospective Studies

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Transplantation, Homologous/adverse effects

KW - Blast Crisis/therapy

KW - Bone Marrow

KW - Neoplasm Recurrence, Local/etiology

KW - Myeloproliferative Disorders/therapy

KW - Transplantation Conditioning

U2 - 10.1002/ajh.26833

DO - 10.1002/ajh.26833

M3 - SCORING: Journal article

C2 - 36606718

VL - 98

SP - 628

EP - 638

JO - AM J HEMATOL

JF - AM J HEMATOL

SN - 0361-8609

IS - 4

ER -